|Bid||1.4250 x 703400|
|Ask||1.3250 x 22100|
|Day's range||1.3500 - 1.3900|
|52-week range||0.6370 - 1.4750|
|PE ratio (TTM)||63.07|
|Forward Dividend & Yield||N/A (N/A)|
|1y target est||0.99|
MELBOURNE, Australia--(BUSINESSWIRE)-- Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that its two phase 3 trials of VivaGel® BV for prevention of recurrent bacterial vaginosis (rBV) achieved their primary objective demonstrating statistically significant superiority compared to placebo in preventing rBV based on topline data. Starpharma intends to submit a marketing application to the FDA for VivaGel® BV for prevention of rBV based on these positive results.
MELBOURNE, Australia--(BUSINESSWIRE)-- Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that it has completed a transaction to sell its agrochemicals and Priostar® business (Starpharma Agrochemicals) to Agrium, Inc., (Agrium) (NYSE: AGU, TSE: AGU) for A$35 million in cash consideration. The Starpharma Agrochemical business will be operated by Agrium’s wholly-owned subsidiary, Loveland Products, Inc. This business is independent of Starpharma’s DEP® and VivaGel® products and related intellectual property portfolios.
MELBOURNE, Australia--(BUSINESSWIRE)-- Starpharma Holdings Ltd (ASX:SPL, OTCQX:SPHRY) is pleased to announce the VivaGel ® condom has been launched in Canada by Ansell (ASX:ANN) under the LifeStyles ® ...
MELBOURNE, Australia--(BUSINESSWIRE)-- Starpharma Holdings Ltd (ASX:SPL, OTCQX:SPHRY) today announced it has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designation for VivaGel® BV by the US Food and Drug Administration (FDA). QIDP and Fast Track designations were granted independently for both the VivaGel® BV treatment and prevention indications for bacterial vaginosis (BV). This positive development recognises the high unmet medical need in the management of BV and the potential of VivaGel® BV to address that need for both treatment and prevention of recurrent BV, markets estimated to be worth in excess of US$1 billion globally.
Starpharma receives $3.5M R&D tax incentive refund Melbourne, Australia; 22 December 2016: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it has received the anticipated $3.5M of R&D ...